Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Cartesian Therapeutics (RNAC) over the last 6 years, with Dec 2024 value amounting to -$4.49.

  • Cartesian Therapeutics' EPS (Weighted Average and Diluted) fell 22.12% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 97.26%. This contributed to the annual value of -$4.49 for FY2024, which is 90.98% up from last year.
  • Cartesian Therapeutics' EPS (Weighted Average and Diluted) amounted to -$4.49 in FY2024, which was up 90.98% from -$49.76 recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.10 during FY2022, and registered a low of -$49.76 during FY2023.
  • In the last 3 years, Cartesian Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$4.49 in 2024 and averaged -$18.05.
  • As far as peak fluctuations go, Cartesian Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 145.45% in 2022, and later crashed by 49,860.00% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$0.68 in 2020, then skyrocketed by 67.65% to -$0.22 in 2021, then skyrocketed by 145.45% to $0.10 in 2022, then crashed by 49,860.00% to -$49.76 in 2023, then spiked by 90.98% to -$4.49 in 2024.